Research Analysts Set Expectations for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities researchers at Cantor Fitzgerald dropped their FY2025 EPS estimates for Solid Biosciences in a note issued to investors on Thursday, May 22nd. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($2.06) for the year, down from their previous estimate of ($1.60). Cantor Fitzgerald has a “Overweight” rating and a $16.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.06).

A number of other research firms have also commented on SLDB. HC Wainwright lifted their price target on shares of Solid Biosciences from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, March 10th. JPMorgan Chase & Co. dropped their price target on shares of Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, March 13th. Wedbush dropped their price target on shares of Solid Biosciences from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Friday, May 16th. Barclays dropped their price target on shares of Solid Biosciences from $15.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, May 16th. Finally, Piper Sandler dropped their price target on shares of Solid Biosciences from $20.00 to $17.00 and set an “overweight” rating on the stock in a research report on Friday, May 16th. Ten investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $14.90.

Solid Biosciences Stock Down 2.8%

NASDAQ:SLDB opened at $2.81 on Monday. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37. The firm has a market cap of $217.82 million, a price-to-earnings ratio of -0.92 and a beta of 2.32. The company’s 50 day moving average is $3.28 and its 200-day moving average is $4.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Woodline Partners LP bought a new position in shares of Solid Biosciences during the 1st quarter worth about $2,338,000. Goldman Sachs Group Inc. increased its stake in Solid Biosciences by 32.2% in the first quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock valued at $667,000 after acquiring an additional 43,910 shares during the period. EcoR1 Capital LLC bought a new stake in Solid Biosciences in the first quarter valued at about $2,754,000. Bain Capital Life Sciences Investors LLC increased its stake in Solid Biosciences by 96.1% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company’s stock valued at $29,273,000 after acquiring an additional 3,877,087 shares during the period. Finally, AQR Capital Management LLC bought a new stake in Solid Biosciences in the first quarter valued at about $418,000. Institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.